公开(公告)号：US10010562B2

公开(公告)日：2018-07-03

申请号：US15033715

申请日：2014-11-03

Applicant: Merck Sharp & Dohme Corp.

Inventor： Steven L. Colletti ,  Thomas J. Tucker ,  David M. Tellers ,  Boyoung Kim ,  Rob Burke ,  Kathleen B. Calati ,  Matthew G. Stanton ,  Rubina G. Parmar ,  Jeffrey G. Aaronson ,  Weimin Wang

IPC: A61K31/713 ,  C12N15/113 ,  C07H15/203 ,  A61K31/7125 ,  A61K38/10 ,  A61K38/16

CPC classification number: A61K31/7125 ,  A61K31/713 ,  A61K38/10 ,  A61K38/16 ,  C07K2319/10 ,  C12N15/111 ,  C12N15/113 ,  C12N15/87 ,  C12N2310/14 ,  C12N2310/351 ,  C12N2320/31

Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.

公开(公告)号：US20190015442A1

公开(公告)日：2019-01-17

申请号：US15974135

申请日：2018-05-08

Applicant: Merck Sharp & Dohme Corp.

Inventor： Steven L. Colletti ,  Thomas J. Tucker ,  David M. Tellers ,  Boyoung Kim ,  Rob Burke ,  Kathleen B. Calati ,  Matthew G. Stanton ,  Rubina G. Parmar ,  Jeffrey G. Aaronson ,  Weimin Wang

IPC: A61K31/7125 ,  C12N15/113 ,  C12N15/87 ,  A61K38/16 ,  A61K38/10 ,  A61K31/713 ,  C12N15/11

CPC classification number: A61K31/7125 ,  A61K31/713 ,  A61K38/10 ,  A61K38/16 ,  C07K2319/10 ,  C12N15/111 ,  C12N15/113 ,  C12N15/87 ,  C12N2310/14 ,  C12N2310/351 ,  C12N2320/31

Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurance of P is independently selected from Table 2; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.

公开(公告)号：US10532068B2

公开(公告)日：2020-01-14

申请号：US15974135

申请日：2018-05-08

Applicant: Merck Sharp & Dohme Corp.

Inventor： Steven L. Colletti ,  Thomas J. Tucker ,  David M. Tellers ,  Boyoung Kim ,  Rob Burke ,  Kathleen B. Calati ,  Matthew G. Stanton ,  Rubina G. Parmar ,  Jeffrey G. Aaronson ,  Weimin Wang

IPC: C12N15/87 ,  A61K31/713 ,  A61K38/10 ,  A61K38/16 ,  C12N15/11 ,  C12N15/113 ,  A61K31/7125

Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.